Wolff Wiese Magana’s BridgeBio Pharma BBIO Stock Holding History

Wolff Wiese Magana’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-27	Closed	-$934	–	994
2025 Q1	$934	Hold	27	–	–	﹤0.01%	861
2024 Q4	$741	Hold	27	–	–	﹤0.01%	849
2024 Q3	$688	Buy	+27	New	+$709	﹤0.01%	892

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Wolff Wiese Magana's BBIO Position: Q2 2025 in Review

Wolff Wiese Magana sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 27 shares — an estimated $934 sold.

Wolff Wiese Magana first reported a position in BBIO in Q3 2024 and held it in 3 quarters. The position peaked at $934 in Q1 2025. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

Wolff Wiese Magana reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
Wolff Wiese Magana sold 27 BridgeBio Pharma shares in Q2 2025, an estimated $934.
Wolff Wiese Magana first reported a position in BridgeBio Pharma in Q3 2024 and held it in 3 quarters.
Wolff Wiese Magana's BridgeBio Pharma position peaked at $934 in Q1 2025.
359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Wolff Wiese Magana's 13F filing for Q2 2025, filed 17 Jul 2025.